Secondary analysis of the phase 3 ARANOTE trial (669 men with mHSPC): darolutamide plus ADT vs placebo delayed pain progression (HR 0.72) and deterioration in FACT-P quality of life (HR 0.76, exploratory); serious AEs 24% in both.
Secondary analysisn = 669
Morgans et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial